These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 22956867

  • 1. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
    Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM.
    Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
    [Abstract] [Full Text] [Related]

  • 2. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [Abstract] [Full Text] [Related]

  • 3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 4. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G, Khera M, Bhattacharya RK, Kushner H, Miner MM.
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [Abstract] [Full Text] [Related]

  • 5. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM, Bhattacharya RK, Blick G, Kushner H, Khera M.
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [Abstract] [Full Text] [Related]

  • 6. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
    Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM.
    Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
    [Abstract] [Full Text] [Related]

  • 7. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL, Morgentaler A.
    Int J Impot Res; 2006 May; 18(2):201-5. PubMed ID: 16177827
    [Abstract] [Full Text] [Related]

  • 8. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [Abstract] [Full Text] [Related]

  • 9. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).
    Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM.
    BMC Endocr Disord; 2011 Nov 01; 11():18. PubMed ID: 22044661
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May 01; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

  • 11. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    Aging Male; 2012 Mar 01; 15(1):14-21. PubMed ID: 22092151
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.
    Int J Impot Res; 2008 Mar 01; 20(2):213-7. PubMed ID: 17898800
    [Abstract] [Full Text] [Related]

  • 13. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC, RHYME Investigators.
    BJU Int; 2017 Feb 01; 119(2):216-224. PubMed ID: 27409523
    [Abstract] [Full Text] [Related]

  • 14. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.
    Int J Impot Res; 2008 Feb 01; 20(6):561-5. PubMed ID: 18843272
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May 01; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 16. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL, Morgentaler A.
    J Urol; 2003 Dec 01; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [Abstract] [Full Text] [Related]

  • 17. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT, Smith TM, Offutt LA.
    J Sex Med; 2009 Sep 01; 6(9):2601-10. PubMed ID: 19549089
    [Abstract] [Full Text] [Related]

  • 18. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.
    J Sex Med; 2014 Nov 01; 11(11):2818-25. PubMed ID: 25131184
    [Abstract] [Full Text] [Related]

  • 19. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    Int Braz J Urol; 2010 Nov 01; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
    [Abstract] [Full Text] [Related]

  • 20. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF, Reid M, Madden W, Burnett AL.
    Andrology; 2013 Jul 01; 1(4):576-82. PubMed ID: 23606509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.